Neurogene Inc. (NGNE) stock
NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
$23.10−0.20 (-0.86%)
Close on Nov 17, 2026Market cap $462.26MP/E –Yield –
Earnings
Neurogene's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 23, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2024
–
EPS, Q3 FY2024
-$1.19
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Neurogene's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 23, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026before the open | – | – | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 11, 2026before the open | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 12, 2026after the close | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 24, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 13, 2025after the close | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 11, 2025after the close | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 9, 2025before the open | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 24, 2025after the close | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 18, 2024after the close | – | – | -$1.19 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 9, 2024before the open | $92.00K | – | -$1.09 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 10, 2024before the open | – | – | -$1.00 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 18, 2024after the close | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022after the close | – | – | -$0.24 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022after the close | – | – | -$0.28 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022after the close | – | – | -$0.28 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 1, 2022after the close | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021after the close | – | – | -$0.28 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 12, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 25, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 9, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 12, 2020after the close | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 6, 2020after the close | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Mar 12, 2020after the close | – | – | – | Filing |
| Q3 FY2019ended Sep 30, 2019 | Nov 13, 2019before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Neurogene has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Neurogene puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Neurogene filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Update
- Update
- Update
- Results
- Results
- Update
- Results
- Results
- Update
- Update
See a number that looks wrong?